WHO Drug Information, Vol. 22, No.3, 2008                                                 Recommended INN: List 60



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 60
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in Cumulative List
No. 12, 2007 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 60
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans
la Liste récapitulative No. 12, 2007 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 60
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente
anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes
Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes
Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en
farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran
reunidas en Cumulative List No. 12, 2007 (disponible sólo en CD-ROM).


                                                                                                                 219
Recommended INN: List 60                                                  WHO Drug Information, Vol. 22, No.3, 2008




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 adipiplonum
 adipiplon                                 7-{[2-(3-fluoropyridin-2-yl)-1H-imidazol-1-yl]methyl}-2-methyl-
                                           8-propyl[1,2,4]triazolo[1,5-c]pyrimidine

 adipiplon                                 7-{[2-(3-fluoropyridin-2-yl)-1H-imidazol-1-yl]méthyl}-2-méthyl-
                                           8-propyl[1,2,4]triazolo[1,5-c]pyrimidine

 adipiplón                                 7-{[2-(3-fluoropiridin-2-il)-1H-imidazol-1-il]metil}-2-metil-
                                           8-propil[1,2,4]triazolo[1,5-c]pirimidina

                                           C18H18FN7

                                                    N
                                                        N     N
                                            H 3C
                                                    N                     F

                                                                  N
                                                                              N
                                                        CH3           N



 agatolimodum
 agatolimod                                P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-
                                           P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-
                                           thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-
                                           (3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
                                           thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-
                                           thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-
                                           thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-
                                           (3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-
                                           thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                           (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-
                                           thymidine

 agatolimod                                P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-
                                           thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-
                                           (3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
                                           thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-
                                           (3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-
                                           déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-P-
                                           thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-
                                           (3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-P-
                                           thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-
                                           thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-thymidine




220
WHO Drug Information, Vol. 22, No.3, 2008                                                  Recommended INN: List 60


 agatolimod                                 P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-
                                            tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-
                                            2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-
                                            (3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-
                                            tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-
                                            2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-
                                            (3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-
                                            tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidill-(3'→5')-
                                            2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-timidina

                                            C236H303N70O133P23S23

                                            DNA, d(P-thio)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T)




 alacizumabum pegolum*
 alacizumab pegol                           immunoglobulin di-Fab’ fragment, anti-[Homo sapiens VEGFR2
                                            (vascular endothelial growth factor receptor 2, KDR, kinase insert
                                            domain receptor, FLK1, CD309)] pegylated humanized monoclonal
                                            antibody di-Fab’ CDP791 (or g165 DFM-PEG); VH-gamma1CH1
                                            [humanized VH (Homo sapiens FR/Mus musculus CDR) [8.8.10] -
                                            Homo sapiens IGHG1*01 CH1-hinge (hinge PPCP12-15>AA)] (220-
                                            214')-disulfide with kappa light chain [humanized V-KAPPA (Homo
                                            sapiens FR/Mus musculus CDR) [6.3.9] -Homo sapiens IGKC*01];
                                            (226-bis-[maleimide-PEG (polyethylene glycol) 20 kDa]-226'')-dimer

 alacizumab pégol                           immunoglobuline fragment di-Fab’, anti-[Homo sapiens VEGFR2
                                            (récepteur 2 du facteur de croissance endothélial vasculaire, KDR,
                                            récepteur à domaine insert kinase, FLK1, CD309)] anticorps
                                            monoclonal di-Fab’ humanisé pégylé CDP791 (or g165 DFM-PEG);
                                            VH-gamma1CH1 [VH humanisé (Homo sapiens FR/Mus musculus
                                            CDR) [8.8.10] -Homo sapiens IGHG1*01 CH1-charnière (charnière
                                            PPCP12-15>AA)] (220-214')-disulfure avec la chaîne légère kappa
                                            [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR) [6.3.9]
                                            -Homo sapiens IGKC*01]; dimère (226-bis-[maléimide-PEG
                                            (polyéthylène glycol) 20 kDa]-226'')

 alacizumab pegol                           inmunoglobulina fragmento di-Fab’, anti-[Homo sapiens VEGFR2
                                            (receptor 2 del factor vascular de crecimiento endotelial, KDR,
                                            receptor con dominio inserto kinasa, FLK1, CD309)] anticuerpo
                                            monoclonal di-Fab’ humanizado pegilado CDP791 (o g165 DFM-
                                            PEG); VH-gamma1CH1 [VH humanizado (Homo sapiens FR/Mus
                                            musculus CDR) [8.8.10] -Homo sapiens IGHG1*01 CH1-región
                                            bisagra (región bisagra PPCP12-15>AA)] (220-214')-disulfuro con la
                                            cadena ligera kappa [V-KAPPA humanizada (Homo sapiens FR/Mus
                                            musculus CDR) [6.3.9] -Homo sapiens IGKC*01]; dímero (226-bis-
                                            [maleimida-PEG (polietilen glicol) 20 kDa]-226'')




                                                                                                                           221
Recommended INN: List 60                                            WHO Drug Information, Vol. 22, No.3, 2008



                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG           LVQPGGSLRL            SCAASGFTFS          SYGMSWVRQA           PGKGLEWVAT     50
                           ITSGGSYTYY           VDSVKGRFTI            SRDNAKNTLY          LQMNSLRAED           TAVYYCVRIG    100
                           EDALDYWGQG           TLVTVSSAST            KGPSVFPLAP          SSKSTSGGTA           ALGCLVKDYF    150
                           PEPVTVSWNS           GALTSGVHTF            PAVLQSSGLY          SLSSVVTVPS           SSLGTQTYIC    200
                           NVNHKPSNTK           VDKKVEPKSC            DKTHTCAA                                               228

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS           LSASVGDRVT            ITCRASQDIA          GSLNWLQQKP           GKAIKRLIYA     50
                           TSSLDSGVPK           RFSGSRSGSD            YTLTISSLQP          EDFATYYCLQ           YGSFPPTFGQ    100
                           GTKVEIKRTV           AAPSVFIFPP            SDEQLKSGTA          SVVCLLNNFY           PREAKVQWKV    150
                           DNALQSGNSQ           ESVTEQDSKD            STYSLSSTLT          LSKADYEKHK           VYACEVTHQG    200
                           LSSPVTKSFN           RGEC                                                                         214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           C22 - C96; C144 - C200; C220 and light chain C214

                           Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                           Heavy chain residue C226 is the site of PEG attachment.




 aleplasininum
 aleplasinin               2-{1-[(4-tert-butylphenyl)methyl]-5-(3-methylphenyl)-1H-indol-3-yl}-
                           2-oxoacetic acid

 aléplasinine              acide [1-{[4-(1,1-diméthyléthyl)phényl]méthyl}-5-(3-méthylphényl)-
                           1H-indol-3-yl]oxoacétique

 aleplasinina              ácido 2-{1-[(4-terc-butilfenil)metil]-5-(3-metilfenil)-1H-indol-3-il}-
                           2-oxoacético

                           C28H27NO3

                                                                O
                             H3C CH3                                     CO2H

                           H3C
                                                           N                                 CH3




 almorexantum
 almorexant                (2R)-2-[(1S)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-
                           3,4-dihydroisoquinolin-2(1H)-yl]-N-methyl-2-phenylacetamide

 almorexant                (2R)-1-[(1S)-6,7-diméthoxy-1-{2-[4-(trifluorométhyl)phényl]éthyl}-
                           3,4-dihydroisoquinoléin-2(1H)-yl]-N-méthyl-2-phénylacétamide

 almorexant                (2R)-2-[(1S)-6,7-dimetoxi-1-{2-[4-(trifluorometil)fenil]etil}-
                           3,4-dihidroisoquinolin-2(1H)-il]-N-metil-2-fenilacetamida

                           C29H31F3N2O3


                           F3C
                                                 H         H
                                                                         H
                           H3CO                                          N
                                                         N                   CH3
                                                                  O
                           H3CO




222
WHO Drug Information, Vol. 22, No.3, 2008                                                 Recommended INN: List 60


 amolimogenum bepiplasmidum*
 amolimogene bepiplasmid                    plasmid DNA vector expressing a hybrid peptide consisting of a
                                            25 amino acid targeting signal sequence fused to the N-terminus of a
                                            236 amino acid peptide derived from fragments of the E6 and E7
                                            genes from HPV types 16 and 18, driven by a cytomegalovirus
                                            promoter

 amolimogène bépliplasmide                  vecteur constitué d’ADN plasmidique exprimant un peptide hybride
                                            composé d’une séquence signal de 25 résidus fusionnée à
                                            l’aminoacide N-terminal d’un peptide de 236 résidus constitué de
                                            fragments du produit des gènes E6 et E7 du Papillomavirus humain
                                            de type 16 et 18 sous contrôle d’un promoteur de cytomégalovirus

 amolimogén bepiplásmido                    vector formado por DNA de plásmido que expresa un péptido híbrido
                                            que consiste en una secuencia señal de 25 aminoácidos unida al
                                            extremo N-terminal de un péptido de 236 aminoácidos constituido
                                            por fragmentos del producto de los genes E6 y E7 del
                                            Papillomavirus humano tipos 16 y 18, controlado por un promotor de
                                            cytomegalovirus




 amsilarotenum
 amsilarotene                               4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid

 amsilarotène                               acide 4-{[3,5-bis(triméthylsilyl)benzoyl]amino}benzoïque

 amsilaroteno                               ácido 4-{[3,5-bis(trimetilsilil)benzoil]amino}benzoico

                                            C20H27NO3Si2

                                                                               CO2H
                                              H3C        CH3          O
                                                    Si
                                            H3C                           N
                                                                          H


                                                               Si CH3
                                                    H3 C
                                                                CH3




 anacetrapibum
 anacetrapib                                (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{4'-fluoro-2'-methoxy-
                                            5'-(propan-2-yl)-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl}methyl)-
                                            4-methyl-1,3-oxazolidin-2-one

 anacétrapib                                (4S,5R)-5-[3,5-bis(trifluorométhyl)phényl]-3-{[4'-fluoro-2'-méthoxy-
                                            5'-(1-méthyléthyl)-4-(trifluorométhyl)biphényl-2-yl]méthyl}-
                                            4-méthyloxazolidin-2-one

 anacetrapib                                (4S,5R)-5-[3,5-bis(trifluorometil)fenil]-3-{[4'-fluoro-2'-metoxi-
                                            5'-(propan-2-il)-4-(trifluorometil)bifenil-2-il]metil}-4-metiloxazolidin-
                                            2-ona




                                                                                                                        223
Recommended INN: List 60                                         WHO Drug Information, Vol. 22, No.3, 2008


                           C30H25F10NO3

                                                                     CF3
                                                            O
                                                  O
                                           H
                           F3 C
                                                        N
                                                H CH
                                                     3                        OCH3
                                       CF3
                                                    H3C

                                                            CH3      F




 anrukinzumabum*
 anrukinzumab              immunoglobulin G1, anti-[Homo sapiens interleukin 13 (IL13)]
                           humanized monoclonal IMA-638; gamma1 heavy chain [humanized
                           VH (Homo sapiens FR/Mus musculus CDR) [8.7.12] -Homo sapiens
                           IGHG1*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1]
                           (221-218')-disulfide with kappa light chain [humanized V-KAPPA
                           (Homo sapiens FR/Mus musculus CDR) [10.3.9] -Homo sapiens
                           IGKC*01]; (227-227'':230-230'')-bisdisulfide dimer

 anrukinzumab              immunoglobuline G1, anti-[Homo sapiens interleukine 13 (IL13)]
                           anticorps monoclonal humanisé IMA-638; chaîne lourde gamma1
                           [VH humanisé (Homo sapiens FR/Mus musculus CDR) [8.7.12] -
                           Homo sapiens IGHG1*03, 97R>K (CH1 120), 117L>A (CH2 1.3),
                           120G>A (CH2 1]] (221-218')-disulfure avec la chaîne légère kappa
                           [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR)
                           [10.3.9] -Homo sapiens IGKC*01]; dimère (227-227'':230-230'')-
                           bisdisulfure

 anrukinzumab              inmunoglobulina G1, anti-[Homo sapiens interleukina 13 (IL13)]
                           anticuerpo monoclonal humanizado IMA-638; cadena pesada
                           gamma1 [VH humanizada (Homo sapiens FR/Mus musculus CDR)
                           [8.7.12] - Homo sapiens IGHG1*03, 97R>K (CH1 120), 117L>A
                           (CH2 1.3), 120G>A (CH2 1]] (221-218')-disulfuro con la cadena
                           ligera kappa [V-KAPPA humanizada (Homo sapiens FR/Mus
                           musculus CDR) [10.3.9] -Homo sapiens IGKC*01]; dímero (227-
                           227'':230-230'')-bisdisulfuro

                           C6452H9954N1714O2024S46

                           Heavy chain γ1 / Chaîne lourde γ1 / Cadena pesada γ1
                           EVQLVESGGG          LVQPGGSLRL        SCAASGFTFI          SYAMSWVRQA         PGKGLEWVAS           50
                           ISSGGNTYYP          DSVKGRFTIS        RDNAKNSLYL          QMNSLRAEDT         AVYYCARLDG           100
                           YYFGFAYWGQ          GTLVTVSSAS        TKGPSVFPLA          PSSKSTSGGT         AALGCLVKDY           150
                           FPEPVTVSWN          SGALTSGVHT        FPAVLQSSGL          YSLSSVVTVP         SSSLGTQTYI           200
                           CNVNHKPSNT          KVDKKVEPKS        CDKTHTCPPC          PAPEALGAPS         VFLFPPKPKD           250
                           TLMISRTPEV          TCVVVDVSHE        DPEVKFNWYV          DGVEVHNAKT         KPREEQYNST           300
                           YRVVSVLTVL          HQDWLNGKEY        KCKVSNKALP          APIEKTISKA         KGQPREPQVY           350
                           TLPPSREEMT          KNQVSLTCLV        KGFYPSDIAV          EWESNGQPEN         NYKTTPPVLD           400
                           SDGSFFLYSK          LTVDKSRWQQ        GNVFSCSVMH          EALHNHYTQK         SLSLSPGK             448

                           Light chain κ / Chaîne légère κ / Cadena ligera κ
                           DIQMTQSPSS          LSASVGDRVT        ITCKASESVD          NYGKSLMHWY         QQKPGKAPKL           50'
                           LIYRASNLES          GVPSRFSGSG        SGTDFTLTIS          SLQPEDFATY         YCQQSNEDPW           100'
                           TFGGGTKVEI          KRTVAAPSVF        IFPPSDEQLK          SGTASVVCLL         NNFYPREAKV           150'
                           QWKVDNALQS          GNSQESVTEQ        DSKDSTYSLS          STLTLSKADY         EKHKVYACEV           200'
                           THQGLSSPVT          KSFNRGEC                                                                      218'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           22-95     22''-95''    23'-92'     23'''-92'''  138'-198' 138'''-198''' 145-201 145''-201''
                           218'-221 218'''-221'' 227-227'' 230-230'' 262-322 262''-322'' 368-426 368''-426''




224
WHO Drug Information, Vol. 22, No.3, 2008                                                                      Recommended INN: List 60




 baminerceptum*
 baminercept                                human tumor necrosis factor receptor superfamily member 3
                                            (lymphotoxin-β receptor, TNF C receptor)-(2-195)-peptide (fragment
                                            of extracellular domain) fusion protein with human immunoglobulin
                                            heavy constant γ1 chain Fc fragment [227 residues, hinge (195-205)
                                                                                                  107
                                            des-(1-4),C5>V, CH2 (206-315), CH3 (316-421) des-K ]

 baminercept                                membre 3 de la superfamille des récepteurs du facteur de nécrose
                                            tumorale humain (récepteur de la lymphotoxine-β ou récepteur du
                                            TNF C)-(2-195)-peptide (fragment du domaine extracellulaire)
                                            protéine de fusion avec le fragment Fc de la chaîne lourde constante
                                            γ1 de l’immunoglobuline humaine [227 residues, dés-(1-4)-
                                                                                              107
                                            [C5>V]charnière (195-205), CH2 (206-315), des-K -CH3 (316-421)]

 baminercept                                miembro 3 de la superfamilia de receptores del factor de necrosis
                                            tumoral humano (receptor de la linfotoxina-β o receptor del TNF C)-
                                            (2-195)-péptido (fragmento del dominio extracelular) proteína de
                                            fusión con el fragmento Fc de la cadena pesada constante γ1 de la
                                            inmunoglobulina humana [227 restos, des(14)-[C5>V]bisagra
                                            (195-205), CH2 (206-315), desK107-CH3 (316-421)]

                                            C4074H6282N1134O1274S68

                                            Monomer / Monomère / Monómero
                                            AVPPYASENQ           TCRDQEKEYY           EPQHRICCSR           CPPGTYVSAK          CSRIRDTVCA      50
                                            TCAENSYNEH           WNYLTICQLC           RPCDPVMGLE           EIAPCTSKRK          TQCRCQPGMF     100
                                            CAAWALECTH           CELLSDCPPG           TEAELKDEVG           KGNNHCVPCK          AGHFQNTSSP     150
                                            SARCQPHTRC           ENQGLVEAAP           GTAQSDTTCK           NPLEPLPPEM          SGTMVDKTHT     200
                                            CPPCPAPELL           GGPSVFLFPP           KPKDTLMISR           TPEVTCVVVD          VSHEDPEVKF     250
                                            NWYVDGVEVH           NAKTKPREEQ           YNSTYRVVSV           LTVLHQDWLN          GKEYKCKVSN     300
                                            KALPAPIEKT           ISKAKGQPRE           PQVYTLPPSR           DELTKNQVSL          TCLVKGFYPS     350
                                            DIAVEWESNG           QPENNYKTTP           PVLDSDGSFF           LYSKLTVDKS          RWQQGNVFSC     400
                                            SVMHEALHNH           YTQKSLSLSP           G                                                       421

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            12-27     12'-27'    28-41      28'-41'     31-49      31'-49'    52-67     52'-67'    70-85
                                            70'-85' 73-93        73'-93'     95-101     95'-101' 108-117 108'-117' 111-136 111'-136'
                                            139-154 139'-154' 201-201' 204-204' 236-296 236'-296' 342-400 342'-400'

                                            Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                                            Asn-9 Asn-9' Asn-146 Asn-146' Asn-272 Asn-272'




 bentamapimodum
 bentamapimod                               2-(1,3-benzothiazol-2-yl)-2-[2-({4-[(morpholin-4-yl)methyl]phenyl}=
                                            methoxy)pyrimidin-4-yl]acetonitrile

 bentamapimod                               (benzothiazol-2-yl)[2-({4-[(morpholin-4-yl)méthyl]phényl}=
                                            méthoxy)pyrimidin-4-yl]acétonitrile

 bentamapimod                               2-(1,3-benzotiazol-2-il)-2-[2-({4-[(morfolin-4-il)metil]fenil}metoxi)=
                                            pirimidin-4-il]acetonitrilo

                                            C25H23N5O2S

                                                     N                                            H CN
                                             O                                    O        N                   N              and enantiomer
                                                                                                                              et énantiomère
                                                                                                                              y enantiómero
                                                                                       N                  S




                                                                                                                                                225
Recommended INN: List 60                                         WHO Drug Information, Vol. 22, No.3, 2008


 berubicinum
 berubicin                 (8S,10S)-10-[(3-amino-4-O-benzyl-2,3,6-trideoxy-α-L-lyxo-
                           hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-
                           1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione

 bérubicine                (8S,10S)-10-[(3-amino-4-O-benzyl-2,3,6-tridéoxy-α-L-lyxo-
                           hexopyranosyl)oxy]-7,8,9,10-tétrahydro-6,8,11-trihydroxy-
                           8-(hydroxyacétyl)-1-méthoxytétracène-5,12-dione

 berubicina                (8S,10S)-10-[(3-amino-4-O-bencil-2,3,6-tridesoxi-α-L-lixo-
                           hexopiranosil)oxi]- 6,8,11-trihidroxi-8-(hidroxiacetil)-1-metoxi-
                           7,8,9,10-tetrahidrotetraceno-5,12-diona

                           C34H35NO11

                                      O       OH                 O
                                                                       OH
                                                                 OH

                                                   H
                             OCH3 O           OH             O O
                                                       CH3
                                               O
                                                       NH2




 besifloxacinum
 besifloxacin              7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-
                           1,4-dihydroquinoline-3-carboxylic acid

 bésifloxacine             (+)-acide 7-[(3R)-3-aminohexahydro-1H-azépin-1-yl]-8-chloro-
                           1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoléine-3-carboxylique

 besifloxacino             ácido 7-[(3R)-3-aminoazepan-1-il]-1-ciclopropil-8-cloro-6-fluoro-
                           4-oxo-1,4-dihidroquinolina-3-carboxílico

                           C19H21ClFN3O3


                                                   Cl
                                          N                  N
                           H2 N
                                  H
                                          F                           CO2H
                                                             O



 betrixabanum
 betrixaban                N-(5-chloropyridin-2-yl)-2-[4-(N,N-
                           dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide

 bétrixaban                N-(5-chloropyridin-2-yl)-2-({4-
                           [(diméthylamino)iminométhyl]benzoyl}amino)-5-méthoxybenzamide

 betrixabán                N-(5-cloropiridin-2-il)-2-[4-(N,N-dimetilcarbamimidoil)benzamido]-5-
                           metoxibenzamida




226
WHO Drug Information, Vol. 22, No.3, 2008                                                                      Recommended INN: List 60


                                            C23H22ClN5O3

                                                                                                   OCH3
                                                                            O
                                                                                                                  Cl
                                                    CH3                          N
                                                                                 H
                                                    N
                                            H3 C                                     O         N        N
                                                                                               H
                                                         NH


 briobaceptum*
 briobacept                                 aspartyl[1-valine,20-asparagine,27-proline](human tumor necrosis
                                            factor receptor superfamily member 13C (BAFF receptor, BlyS
                                            receptor 3 or CD268 antigen)-(1-71)-peptidyl (part of the extracellular
                                            domain))valyl(human immunoglobulin G1 Fc fragment, Homo
                                            sapiens IGHG1-(104-329)-peptide) (79-79':82-82')-bisdisulfide dimer

 briobacept                                 aspartyl[1-valine,20-asparagine,27-proline](membre 13C de la
                                            superfamille des récepteurs du facteur de nécrose tumorale humain
                                            (récepteur du BAFF, récepteur 3 du BlyS ou antigène CD268)-
                                            (1-71)-peptidyl (fragment du domaine extracellulaire))valyl(fragment
                                            Fc de l’immunoglobuline G1 humaine, Homo sapiens IGHG1-(104-
                                            329)-peptide) (79-79':82-82')-bisdisulfure du dimère

 briobacept                                 aspartill[1-valina,20-asparagina,27-prolina](miembro 13C de la
                                            superfamilia de receptores del factor de necrosis tumoral humano
                                            (receptor del BAFF, receptor 3 del BlyS o antígeno CD268)-(1-71)-
                                            peptidil (fragmento del dominio extracelular))valil(fragmento Fc de la
                                            inmunoglobulina G1 humana, Homo sapiens IGHG1-(104-329)-
                                            péptido) (79-79':82-82')-bisdisulfuro del dímero

                                            C2910H4542N814O878S24

                                            Monomer / Monomère / Monómero
                                            DVRRGPRSLR           GRDAPAPTPC           NPAECFDPLV            RHCVACGLLR          TPRPKPAGAS     50
                                            SPAPRTALQP           QESVGAGAGE           AAVDKTHTCP            PCPAPELLGG          PSVFLFPPKP    100
                                            KDTLMISRTP           EVTCVVVDVS           HEDPEVKFNW            YVDGVEVHNA          KTKPREEQYN    150
                                            STYRVVSVLT           VLHQDWLNGK           EYKCKVSNKA            LPAPIEKTIS          KAKGQPREPQ    200
                                            VYTLPPSRDE           LTKNQVSLTC           LVKGFYPSDI            AVEWESNGQP          ENNYKTTPPV    250
                                            LDSDGSFFLY           SKLTVDKSRW           QQGNVFSCSV            MHEALHNHYT          QKSLSLSPG     249


                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            20-33 20'-33' 25-36 25'-36' 79-79' 82-82' 114-174 114'-174' 220-278 220'-278                '

 cabazitaxelum
 cabazitaxel                                1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-
                                            2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tert-
                                            butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate]

 cabazitaxel                                (-)-12b-acétate 12-benzoate et 9-[(2R,3S)-3-{[(1,1-
                                            diméthyléthoxy)carbonyl]amino}-2-hydroxy-3-phénylpropanoate] de
                                            (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-11-hydroxy-4,6-
                                            diméthoxy-4a,8,13,13-tétraméthyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-
                                            décahydro-7,11-méthano-1H-cyclodéca[3,4]benzo[1,2-b]oxète-
                                            9,12,12b(2aH)-triyle

 cabazitaxel                                4-acetato 2-benzoato 13-[(2R,3S)-3-{[(terc-butoxi)carbonil]amino}-
                                            2-hidroxipropanoato] de 1-hidroxi-7β,10β-dimetoxi-9-oxo-5β,20-
                                            epoxitax-11-eno-2α,4,13α-triil




                                                                                                                                               227
Recommended INN: List 60                                              WHO Drug Information, Vol. 22, No.3, 2008


                           C45H57NO14

                                                                          OCH3 O
                                                                      H                          OCH3
                                                        H3C
                                                                                              CH3 H
                                      HO H
                                                        O                         CH3
                                                                                                  H     H
                                                        H                         CH3
                                 HN H               O
                                            O                                                 O         O
                                                                      OH              H
                                   O
                                            CH3                                   O O             CH3
                                            CH3
                                 H3 C                                     O



 cariprazinum
 cariprazine               3-(trans-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl)-
                           1,1-dimethylurea

 cariprazine               N'-(trans-4-{2-[4-(2,3-dichlorophényl)pipérazin-1-yl]éthyl}cyclohexyl)-
                           N,N-diméthylurée

 cariprazina               N'-(trans-4-{2-[4-(2,3-diclorofenil)piperazin-1-il]etil}ciclohexil)-
                           N,N-dimetilurea

                           C21H32Cl2N4O

                                  CH3
                                            H
                                  N         N
                           H3C
                                        O
                                                                              N                   Cl
                                                                                      N                 Cl




 carmegliptinum
 carmegliptin              (4S)-1-{(2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-
                           hexahydro-2H-benzo[a]quinolizin-3-yl}-4-(fluoromethyl)pyrrolidin-
                           2-one

 carmégliptine             (4S)-1-[(2S,3S,11bS)-2-amino-9,10-diméthoxy-1,3,4,6,7,11b-
                           hexahydro-2H-pyrido[2,1-a]isoquinoléin-3-yl]-4-(fluorométhyl)=
                           pyrrolidin-2-one

 carmegliptina             (4S)-1-{(2S,3S,11bS)-2-amino-9,10-dimetoxi-1,3,4,6,7,11b-
                           hexahidro-2H-benzo[a]quinolizin-3-il}-4-(fluorometil)pirrolidin-2-ona

                           C20H28FN3O3

                                                                      O
                                                    H2N       H
                                                                  H
                                                                                          F
                                                                      N
                                                H
                           H3CO
                                                          N                       H

                           H3CO




228
WHO Drug Information, Vol. 22, No.3, 2008                                                                      Recommended INN: List 60




 cobiprostonum
 cobiprostone                               7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-methylpentyl]-2-hydroxy-
                                            6-oxooctahydrocyclopenta[b]pyran-5-yl}heptanoic acid

 cobiprostone                               acide 7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-methylpentyl]-
                                            2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl}heptanoïque

 cobiprostona                               ácido 7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-metilpentil]-
                                            2-hidroxi-6-oxooctahidrociclopenta[b]piran-5-il}heptanoico

                                            C21H34F2O5

                                                 O       H
                                                                                        CO2H

                                                              H
                                             H
                                                 O

                                             HO
                                                     F       F H     CH3
                                                                 CH3



 conestatum alfa*
 conestat alfa                              human plasma protease C1 inhibitor (C1 esterase inhibitor)
                                            (N,O-glycosylated recombinant protein expressed in the mammary
                                            gland of transgenic rabbits), glycoform α

 conestat alfa                              inhibiteur de la protéase plasmatique C1 humain (inhibiteur de
                                            l’esterase C1) (protéine N,O-glycosylée recombinante exprimée
                                            dans la glande mammaire de lapines transgéniques), glycoforme α

 conestat alfa                              inhibidor de la proteasa plasmática C1 humana (inhibidor de la
                                            esterasa C1) (proteína N,O-glicosilada recombinante expresada en
                                            glándula mamaria de coneja transgénica), glicoforma α

                                            C2355H3745N613O728S17

                                            NPNATSSSSQ            DPESLQDRGE          GKVATTVISK           MLFVEPILEV           SSLPTTNSTT     50
                                            NSATKITANT            TDEPTTQPTT          EPTTQPTIQP           TQPTTQLPTD           SPTQPTTGSF    100
                                            CPGPVTLCSD            LESHSTEAVL          GDALVDFSLK           LYHAFSAMKK           VETNMAFSPF    150
                                            SIASLLTQVL            LGAGENTKTN          LESILSYPKD           FTCVHQALKG           FTTKGVTSVS    200
                                            QIFHSPDLAI            RDTFVNASRT          LYSSSPRVLS           NNSDANLELI           NTWVAKNTNN    250
                                            KISRLLDSLP            SDTRLVLLNA          IYLSAKWKTT           FDPKKTRMEP           FHFKNSVIKV    300
                                            PMMNSKKYPV            AHFIDQTLKA          KVGQLQLSHN           LSLVILVPQN           LKHRLEDMEQ    350
                                            ALSPSVFKAI            MEKLEMSKFQ          PTLLTLPRIK           VTTSQDMLSI           MEKLEFFDFS    400
                                            YDLNLCGLTE            DPDLQVSAMQ          HQTVLELTET           GVEAAAASAI           SVARTLLVFE    450
                                            VQQPFLFVLW            DQQHKFPVFM          GRVYDPRA                                                478

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            101-406 108-183

                                            Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                                            Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61
                                            Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-250 Asn-330




                                                                                                                                                229
Recommended INN: List 60                                            WHO Drug Information, Vol. 22, No.3, 2008


 dacetuzumabum*
 dacetuzumab               immunoglobulin G1, anti-[Homo sapiens CD40 (TNF receptor
                           superfamily member 5, TNFRSF5)] humanized monoclonal SGN-40
                           (or huS2C6); gamma1 heavy chain [humanized VH (Homo sapiens
                           FR/Mus musculus CDR) [8.8.7] -Homo sapiens IGHG1*03, 97R>K
                           (CH1 120)] (217-219')-disulfide with kappa light chain humanized
                           V-KAPPA (Homo sapiens FR/Mus musculus CDR) [11.3.9] -Homo
                           sapiens IGKC*01]; (223-223'':226-226'')-bisdisulfide dimer

 dacétuzumab               immunoglobuline G1, anti-[Homo sapiens CD40 (membre 5 de la
                           superfamille des récepteurs du TNF, TNFRSF5)] anticorps
                           monoclonal humanisé SGN-40 (ou huS2C6); chaîne lourde gamma1
                           [VH humanisé (Homo sapiens FR/Mus musculus CDR) [8.8.7] -
                           Homo sapiens IGHG1*03, 97R>K (CH1 120)] (217-219')-disulfure
                           avec la chaîne légère kappa [V-KAPPA humanisé (Homo sapiens
                           FR/Mus musculus CDR) [11.3.9] -Homo sapiens IGKC*01]; dimère
                           (223-223'':226-226'')-bisdisulfure

 dacetuzumab               inmunoglobulina G1, anti-[Homo sapiens CD40 (miembro 5 de la
                           superfamilia de receptores del TNF, TNFRSF5)] anticuerpo
                           monoclonal humanizado SGN-40 (o huS2C6); cadena pesada
                           gamma1 [VH humanizado (Homo sapiens FR/Mus musculus CDR)
                           [8.8.7] - Homo sapiens IGHG1*03, 97R>K (CH1 120)] (217-219')-
                           disulfuro con la cadena ligera kappa [V-KAPPA humanizada (Homo
                           sapiens FR/Mus musculus CDR) [11.3.9] -Homo sapiens IGKC*01];
                           dímero (223-223'':226-226'')-bisdisulfuro

                           C6452H9964N1732O1998S42

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG           LVQPGGSLRL           SCAASGYSFT           GYYIHWVRQA           PGKGLEWVAR     50
                           VIPNAGGTSY           NQKFKGRFTL           SVDNSKNTAY           LQMNSLRAED           TAVYYCAREG    100
                           IYWWGQGTLV           TVSSASTKGP           SVFPLAPSSK           STSGGTAALG           CLVKDYFPEP    150
                           VTVSWNSGAL           TSGVHTFPAV           LQSSGLYSLS           SVVTVPSSSL           GTQTYICNVN    200
                           HKPSNTKVDK           KVEPKSCDKT           HTCPPCPAPE           LLGGPSVFLF           PPKPKDTLMI    250
                           SRTPEVTCVV           VDVSHEDPEV           KFNWYVDGVE           VHNAKTKPRE           EQYNSTYRVV    300
                           SVLTVLHQDW           LNGKEYKCKV           SNKALPAPIE           KTISKAKGQP           REPQVYTLPP    350
                           SREEMTKNQV           SLTCLVKGFY           PSDIAVEWES           NGQPENNYKT           TPPVLDSDGS    400
                           FFLYSKLTVD           KSRWQQGNVF           SCSVMHEALH           NHYTQKSLSL           SPGK          444

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS           LSASVGDRVT           ITCRSSQSLV           HSNGNTFLHW           YQQKPGKAPK     50'
                           LLIYTVSNRF           SGVPSRFSGS           GSGTDFTLTI           SSLQPEDFAT           YFCSQTTHVP    100'
                           WTFGQGTKVE           IKRTVAAPSV           FIFPPSDEQL           KSGTASVVCL           LNNFYPREAK    150'
                           VQWKVDNALQ           SGNSQESVTE           QDSKDSTYSL           SSTLTLSKAD           YEKHKVYACE    200'
                           VTHQGLSSPV           TKSFNRGEC                                                                    219'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           22-96      22''-96''    23'-93'     23'''-93''' 139'-199' 139'''-199''' 141-197 141''-197''
                           217-219' 217''-219''' 223-223'' 226-226'' 258-318 258''-318'' 364-422 364''-422''



 daporinadum
 daporinad                 (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-
                           2-enamide

 daporinad                 (2E)-N-[4-(1-benzoylpipéridin-4-yl)butyl]-3-(pyridin-3-yl)prop-
                           2-énamide

 daporinad                 (2E)-N-[4-(1-benzoilpiperidin-4-il)butil]-3-(piridin-3-il)prop-2-enamida

                           C24H29N3O2

                               N
                                                       H
                                                       N

                                                  O                                     N

                                                                                             O


230
WHO Drug Information, Vol. 22, No.3, 2008                                                                Recommended INN: List 60




 darinaparsinum
 darinaparsin                               L-γ-glutamyl-S-(dimethylarsanyl)-L-cysteinylglycine

 darinaparsine                              L-γ-glutamyl-S-(diméthylarsanyl)-L-cystéinylglycine

 darinaparsina                              L-γ-glutamil-S-(dimetilarsanil)-L-cisteinilglicina

                                            C12H22AsN3O6S

                                                  H NH2                      O
                                                                     H
                                                                     N
                                            HO2C                                     N        CO2H
                                                                                     H
                                                             O        H
                                                                        S
                                                                         As CH3
                                                                      H3C


 dexnebivololum
 dexnebivolol                               (1R)-2-({(2R)-2-[(2S)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-
                                            2-hydroxyethyl}amino)-1-[(2R)-6-fluoro-3,4-dihydro-2H-chromen-
                                            2-yl]ethanol

 dexnébivolol                               (1R,1'R)-1,1'-[(2R,2'S)-bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-
                                            2-yl)]-2,2'-azanediyldiéthanol

 dexnebivolol                               (1R)-2-({(2R)-2-[(2S)-6-fluoro-3,4-dihidro-2H-cromen-2-il]-
                                            2-hidroxietil}amino)-1-[(2R)-6-fluoro-3,4-dihidro-2H-cromen-
                                            2-il]etanol

                                            C22H25F2NO4

                                                                 H OH            HO H
                                                                             H
                                                         O                   N                 O
                                                                  H                      H
                                            F                                                                F


 emricasanum
 emricasan                                  (3S)-3-{(2S)-2-[N-(2-tert-butylphenyl)oxamoylamino]propanamido}-
                                            4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid

 emricasan                                  acide (3S)-3-({(2S)-2-[({[2-(1,1-diméthyléthyl)phényl]amino}=
                                            oxoacétyl)amino]propanoyl}amino)-4-oxo-
                                            5-(2,3,5,6-tétrafluorophénoxy)pentanoïque

 emricasán                                  ácido (3S)-3-{(2S)-2-[N-(2-terc-butilfenil)oxamoilamino]=
                                            propanamido}-4-oxo-5-(2,3,5,6-tetrafluorofenoxi)pentanoico

                                            C26H27F4N3O7

                                                                                                            F
                                                                                             CO2H    F
                                                             O                   O            H
                                                                      H
                                                                      N
                                                        N                            N               O           F
                                                        H                            H
                                                     CH3         O       H   CH3               O            F
                                            H3C
                                                    CH3




                                                                                                                              231
Recommended INN: List 60                                           WHO Drug Information, Vol. 22, No.3, 2008


 eribaxaban
                                           1                                       2
 eribaxaban                (2R,4R)- N -(4-chlorophenyl)- N -[2-fluoro-4-(2-oxopyridin-
                           1(2H)-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide
                                           1                                   2
 éribaxaban                (2R,4R)-N -(4-chlorophényl)-N -[2-fluoro-4-(2-oxopyridin-
                           1(2H)-yl)phényl]-4-méthoxypyrrolidine-1,2-dicarboxamide
                                           1                           2
 eribaxabán                (2R,4R)- N -(4-clorofenil)- N -[2-fluoro-4-(2-oxopiridin-1(2H)-il)fenil]-
                           4-metoxipirrolidina-1,2-dicarboxamida

                           C24H22ClFN4O4

                                                                       H
                                                                               OCH3
                                                       H H
                                                       N                                   Cl
                                                                   N
                                                           O
                                   N                   F       O           N
                                                                           H
                                       O


 ezatiostatum
 ezatiostat                ethyl [(4S)-4-amino-5-ethoxy-5-oxopentanoyl]-S-benzyl-L-cysteinyl-
                           D-2-phenylglycinate

 ézatiostat                (2R)-[(4S)-4-amino-5-éthoxy-5-oxopentanoyl]-S-benzyl-L-cystéinyl-
                           2-phénylglycinate d’éthyle

 ezatiostat                (2R)-[(4S)-4-amino-5-etoxi-5-oxopentanoil]-S-bencil-L-cisteinil-
                           2-fenilglicinato de etilo

                           C27H35N3O6S



                                               H NH2                               O   H
                                                                   H
                           H3C         O                           N                            O   CH3
                                                                                       N
                                                                                       H
                                               O               O    H                      O
                                                                           S




 fasobegronum
 fasobegron                4'-(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)-
                           3-methoxy-[1,1'-biphenyl]-4-carboxylic acid

 fasobégron                acide 4'-(2-{[(2R)-2-(3-chlorophényl)-2-hydroxyéthyl]amino}éthyl)-
                           3-méthoxybiphényle-4-carboxylique

 fasobegrón                ácido 4'-(2-{[(2R)-2-(3-clorofenil)-2-hidroxietil]amino}etil)-[1,1'-bifenil]-
                           3-metoxi-4-carboxílico

                           C24H24ClNO4

                                   H OH
                                                   H
                                                   N

                                                                                           OCH3

                              Cl
                                                                                           CO2H


232
WHO Drug Information, Vol. 22, No.3, 2008                                                                    Recommended INN: List 60




 favipiravirum
 favipiravir                                6-fluoro-3-hydroxypyrazine-2-carboxamide

 favipiravir                                6-fluoro-3-hydroxypyrazine-2-carboxamide

 favipiravir                                6-fluoro-3-hidroxipirazina-2-carboxamida

                                            C5H4FN3O2

                                                             O
                                            F        N
                                                                  NH2

                                                     N       OH


 fermagatum
 fermagate                                  diiron(III) tetramagnesium carbonate dodecahydroxide—water (1/4)
                                                                                                                                -
 fermagate                                  tétrahydrate de carbonate et bis[(OC-6-11)-hexahydroxyferrate(3 )]
                                            de tétramagnésium

 fermagato                                  dodecahidróxidocarbonato de dihierro(III) y tetramagnesio—
                                            agua(1/4)

                                            CH12Fe2Mg4O15 . 4 H2O

                                                                                               3-
                                                                                    OH
                                                                        HO               OH
                                            4 Mg2+       CO32-     2                Fe                 .     4 H2O
                                                                        HO               OH
                                                                                    OH


 flopristinum
 flopristin                                 (3R,4R,5E,10E,12E,14S,16R,26aR)-16-fluoro-14-hydroxy-
                                            4,12-dimethyl-3-(propan-2-yl)-3,4,8,9,14,15,16,17,24,25,26,26a-
                                            dodecahydro-1H,7H,22H-21,18-azenopyrrolo=
                                            [2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,22-trione

 flopristine                                (3R,4R,5E,10E,12E,14S,16R,26aR)-16-fluoro-14-hydroxy-
                                            4,12-diméthyl-3-(1-méthyléthyl)-8,9,14,15,16,17,24,25,26,26a-
                                            décahydro-3H-21,18-nitrilo-1H,22H-pyrrolo=
                                            [2,1-c][1,8,4,19]dioxadiazacyclotétracosine-1,7,22(4H)-trione

 flopristina                                (3R,4R,5E,10E,12E,14S,16R,26aR)-16-fluoro-14-hidroxi-
                                            4,12-dimetil-3-(propan-2-il)-3,4,8,9,14,15,16,17,24,25,26,26a-
                                            dodecahidro-1H,7H,22H-21,18-azenopirrolo=
                                            [2,1-c][1,8,4,19]dioxadiazaciclotetracosina-1,7,22-triona

                                            C28H38FN3O6


                                                     O                                   H3C
                                                                        N                              CH3
                                                                                         O
                                                         N                                         H
                                            H                   O           H
                                                                                    O              CH3
                                            F                CH3
                                                H                               H              H
                                                                                N
                                                HO
                                                                                    O




                                                                                                                                    233
Recommended INN: List 60                                      WHO Drug Information, Vol. 22, No.3, 2008


 folitixorinum
 folitixorin               N-{4-[(6aRS)-3-amino-1-oxo-1,4,5,6,6a,7-hexahydroimidazo=
                           [1,5-f]pteridin-8(9H)-yl]benzoyl}-L-glutamic acid

 folitixorine              acide N-{4-[(6aRS)-3-amino-1-oxo-1,4,5,6,6a,7-
                           hexahydroimidazo[1,5-f]ptéridin-8(9H)-yl]benzoyl}-L-glutamique


 folitixorina              ácido N-{4-[(6aRS)-3-amino-1-oxo-1,4,5,6,6a,7-
                           hexahidroimidazo[1,5-f]pteridin-8(9H)-il]benzoil}-L-glutámico

                           C20H23N7O6

                                                                        O       H   CO2H

                                         O                                  N
                                                                            H                and epimer at C*
                                     N                                                       et l'épimère en C*
                                                          N                             CO2H y el epímero al C*
                           H2N                    N
                                  HN              *
                                         HN           H


 ibodutantum
 ibodutant                 6-methyl-N-{1-[({(1R)-1-[({1-[(tetrahydro-2H-pyran-
                           4-yl)methyl]piperidin-4-yl}methyl)amino]-3-phenyl-1-oxopropan-
                           2-yl}amino)carbonyl]cyclopentyl}-1-benzothiophene-2-carboxamide

 ibodutant                 N-[1-({(1R)-1-benzyl-2-oxo-2-[({1-[(tétrahydro-2H-pyran-
                           4-yl)méthyl]pipéridin-4-yl}méthyl)amino]éthyl}carbamoyl)cyclopentyl]-
                           6-méthyl-1-benzothiophène-2-carboxamide

 ibodutant                 N-[1-({(1R)-1-bencil-2-oxo-2-[({1-[(tetrahidro-2H-piran-
                           4-il)metil]piperidin-4-il}metil)amino]etil}carbamoil)ciclopentil]-6-metil-
                           1-benzotiofeno-2-carboxamida

                           C37H48N4O4S

                                                      O                     O
                                                                    H
                                          S                         N
                                                          N                         N                     O
                                                          H                         H
                                                                O           H                 N
                           H3C




 imegliminum
 imeglimin                 (4R)-6-(dimethylamino)-4-methyl-4,5-dihydro-1,3,5-triazin-2-amine

 iméglimine                (+)-(6R)-1,6-dihydro-N,N,6-triméthyl-1,3,5-triazine-2,4-diamine

 imeglimina                (4R)-6-(dimetilamino)-4-metil-4,5-dihidro-1,3,5-triazin-2-amina

                           C6H13N5

                                  H CH3

                                 N       NH
                                                  CH3
                           H2N       N        N
                                              CH3




234
WHO Drug Information, Vol. 22, No.3, 2008                                                 Recommended INN: List 60




 laromustinum
 laromustine                                2-(2-chloroethyl)-1,2-bis(methanesulfonyl)-
                                            N-methylhydrazinecarboxamide

 laromustine                                2'-(2-chloroéthyl)-N-méthyl-1',2'-bis(méthylsulfonyl)=
                                            carbamohydrazide

 laromustina                                2-(2-cloroetil)-1,2-bis(metanosulfonil)-N-metilhidrazinacarboxamida

                                            C6H14ClN3O5S2

                                                         O
                                                            CH3
                                                      O O S
                                            H3C                   N
                                                  N           N           Cl
                                                  H
                                                      O       S
                                                                  CH3
                                                          O


 levonebivololum
 levonebivolol                              (1S)-2-({(2S)-2-[(2R)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-
                                            2-hydroxyethyl}amino)-1-[(2S)-6-fluoro-3,4-dihydro-2H-chromen-
                                            2-yl]ethanol

 lévonébivolol                              (1S,1'S)-1,1'-[(2R,2'S)-bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-
                                            2-yl)]-2,2'-azanediyldiéthanol

 levonebivolol                              (1S)-2-({(2S)-2-[(2R)-6-fluoro-3,4-dihidro-2H-cromen-2-il]-
                                            2-hidroxietil}amino)-1-[(2S)-6-fluoro-3,4-dihidro-2H-cromen-
                                            2-il]etanol

                                            C22H25F2NO4

                                                                  HO H         H OH
                                                                          H
                                                              O           N           O
                                                                      H         H
                                            F                                                 F


 linopristinum
 linopristin                                N-{(6R,9S,10R,13S,15aS,22S,24aS)-22-{[4-
                                            (dimethylamino)phenyl]methyl}-6-ethyl-10,23-dimethyl-
                                            18-[(morpholin-4-yl)methyl]-5,8,12,15,21,24-hexaoxo-13-phenyl-
                                            1,2,3,5,6,7,8,9,10,11,12,13,14,15,15a,16,19,21,22,23,24,24a-
                                            docosahydropyrido[2,1-f]pyrrolo[2,1-l][1,4,7,10,13,16]=
                                            oxapentaazacyclononadecin-9-yl}-3-hydroxypyridine-2-carboxamide

 linopristine                               (6R,9S,10R,13S,15aS,22S,24aS)-22-{[4-(diméthylamino)=
                                            phényl]méthyl}-6-éthyl-9-{[(3-hydroxypyridin-2-yl)carbonyl]amino}-
                                            10,23-diméthyl-18-[(morpholin-4-yl)méthyl]-13-phényl-
                                            1,2,3,6,7,9,10,13,14,16,19,22,23,24a-tétradécahydro-
                                            12H-pyrido[2,1-f]pyrrolo[2,1-l][1,4,7,10,13,16]=
                                            oxapentaazacyclononadécine-5,8,12,15,21,24(15aH)-hexone

 linopristina                               N-{(6R,9S,10R,13S,15aS,22S,24aS)-22-{[4-(dimetilamino)fenil]=
                                            metil}-6-etil-13-fenil-10,23-dimetil-18-[(morfolin-4-il)metil]-
                                            5,8,12,15,21,24-hexaoxo-
                                            1,2,3,5,6,7,8,9,10,11,12,13,14,15,15a,16,19,21,22,23,24,24a-
                                            docosahidropirido[2,1-f]pirrolo[2,1-l][1,4,7,10,13,16]=
                                            oxapentaazaciclononadecin-9-il}-3-hidroxipiridina-2-carboxamida



                                                                                                                  235
Recommended INN: List 60                                              WHO Drug Information, Vol. 22, No.3, 2008


                           C50H63N9O10

                             H3C                                  CH3
                                   N                                H
                                                                  N
                             H3C                       H                         N
                                                                                               CH3
                                                                       O
                                     N                  N         O         O              H
                           O                                      O                  HN        O
                                                                       O                             O        OH
                                                        H
                                                            HN                  O
                                                                                         N
                                                                                H      H H
                                                                      H              CH3                 N




 lucatumumabum*
 lucatumumab               immunoglobulin G1, anti-[Homo sapiens CD40 (TNF receptor
                           superfamily member 5, TNFRSF5)] human monoclonal antibody
                           CHIR-12.12; gamma1 heavy chain [Homo sapiens VH [8.8.13] -
                           IGHG1*03 (CH1 S10>A), no C-terminal lysine] from clone CHIR-
                           12.12 (223-219’)-disulfide with kappa light chain [Homo sapiens
                           V-KAPPA (IGKV2-28-IGJK3*01, K12>R) [11.3.9] -IGKC*01] from
                           clone CHIR-12.12; (229-229”:232-232”)-bisdisulfide dimer

 lucatumumab               immunoglobuline G1, anti-[Homo sapiens CD40 (membre 5 de la
                           superfamille des récepteurs du TNF, TNFRSF5)] anticorps
                           monoclonal humain CHIR-12.12; chaîne lourde gamma1 [Homo
                           sapiens VH [8.8.13] -IGHG1*03 (CH1 S10>A), pas de lysine
                           C-terminale] du clone CHIR-12.12 (223-219’)-disulfure avec la
                           chaîne légère kappa [Homo sapiens V-KAPPA (IGKV2-28-IGJK3*01,
                           K12>R) [11.3.9] -IGKC*01] du clone CHIR-12.12; dimère (229-
                           229”:232-232”)-bisdisulfure

 lucatumumab               inmunoglobulina G1, anti-[Homo sapiens CD40 (miembro 5 de la
                           superfamilia de receptores del TNF, TNFRSF5)] anticuerpo
                           monoclonal humano CHIR-12.12; cadena pesada gamma1 [Homo
                           sapiens VH [8.8.13] -IGHG1*03 (CH1 S10>A), sin lisina C-terminal]
                           del clon CHIR-12.12 (223-219’)-disulfuro con la cadena ligera kappa
                           [Homo sapiens V-KAPPA (IGKV2-28-IGJK3*01, K12>R) [11.3.9] -
                           IGKC*01] del clon CHIR-12.12; dímero (229-229”:232-232”)-
                           bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVESGGG           VVQPGRSLRL            SCAASGFTFS            SYGMHWVRQA             PGKGLEWVAV    50
                           ISYEESNRYH           ADSVKGRFTI            SRDNSKITLY            LQMNSLRTED             TAVYYCARDG   100
                           GIAAPGPDYW           GQGTLVTVSS            ASTKGPSVFP            LAPASKSTSG             GTAALGCLVK   150
                           DYFPEPVTVS           WNSGALTSGV            HTFPAVLQSS            GLYSLSSVVT             VPSSSLGTQT   200
                           YICNVNHKPS           NTKVDKRVEP            KSCDKTHTCP            PCPAPELLGG             PSVFLFPPKP   250
                           KDTLMISRTP           EVTCVVVDVS            HEDPEVKFNW            YVDGVEVHNA             KTKPREEQYN   300
                           STYRVVSVLT           VLHQDWLNGK            EYKCKVSNKA            LPAPIEKTIS             KAKGQPREPQ   350
                           VYTLPPSREE           MTKNQVSLTC            LVKGFYPSDI            AVEWESNGQP             ENNYKTTPPV   400
                           LDSDGSFFLY           SKLTVDKSRW            QQGNVFSCSV            MHEALHNHYT             QKSLSLSPGK   450

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQSPLS           LTVTPGEPAS            ISCRSSQSLL            YSNGYNYLDW             YLQKPGQSPQ    50
                           VLISLGSNRA           SGVPDRFSGS            GSGTDFTLKI            SRVEAEDVGV             YYCMQARQTP   100
                           FTFGPGTKVD           IRRTVAAPSV            FIFPPSDEQL            KSGTASVVCL             LNNFYPREAK   150
                           VQWKVDNALQ           SGNSQESVTE            QDSKDSTYSL            SSTLTLSKAD             YEKHKVYACE   200
                           VTHQGLSSPV           TKSFNRGEC                                                                       219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Light Chain Intrachain: C23-C93, C149-C199
                           Heavy Chain Intrachain: C22-C96, C147-C203, C264-C324, C369-C428
                           Interchain: Light Chain: C219-Heavy Chain 223, Heavy Chain 1 C229-Heavy Chain 2 C229,
                           Heavy Chain 1 C232 - Heavy Chain 2 C232




236
WHO Drug Information, Vol. 22, No.3, 2008                                                                       Recommended INN: List 60


 milatuzumabum*
 milatuzumab                                immunoglobulin G1, anti-[Homo sapiens CD74 (major
                                            histocompatibility complex class II invariant chain)] humanized
                                            monoclonal IMMU-115 (or hLL1); gamma1 heavy chain [humanized
                                            VH (Homo sapiens FR/Mus musculus CDR) [8.8.13] -Homo sapiens
                                            IGHG1*03] (223-219')-disulfide with kappa light chain [humanized
                                            V-KAPPA (Homo sapiens FR/Mus musculus CDR) [11.3.9] -Homo
                                            sapiens IGKC*01]; (229-229'':232-232'')-bisdisulfide dimer

 milatuzumab                                immunoglobuline G1, anti-[Homo sapiens CD74 (chaîne invariante
                                            du complexe majeur d’histocompatibilité de classe II)] anticorps
                                            monoclonal humanisé IMMU-115 (ou hLL1); chaîne lourde gamma1
                                            [VH humanisé (Homo sapiens FR/Mus musculus CDR) [8.8.13] -
                                            Homo sapiens IGHG1*03] (223-219')-disulfure avec la chaîne légère
                                            kappa [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR)
                                            [11.3.9] -Homo sapiens IGKC*01]; dimère (229-229'':232-232'')-
                                            bisdisulfure

 milatuzumab                                inmunoglobulina G1, anti-[Homo sapiens CD74 (cadena invariable
                                            del complejo mayor de histocompatibilidad de clase II)] anticuerpo
                                            monoclonal humanizado IMMU-115 (o hLL1); cadena pesada
                                            gamma1 [VH humanizado (Homo sapiens FR/Mus musculus CDR)
                                            [8.8.13] - Homo sapiens IGHG1*03] (223-219')-disulfuro con la
                                            cadena ligera kappa [V-KAPPA humanizada (Homo sapiens FR/Mus
                                            musculus CDR) [11.3.9] -Homo sapiens IGKC*01]; dímero (229-
                                            229'':232-232'')-bisdisulfuro

                                            C6518H10066N1758O2020S40

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLQQSGSE           LKKPGASVKV           SCKASGYTFT           NYGVNWIKQA           PGQGLQWMGW    50
                                            INPNTGEPTF           DDDFKGRFAF           SLDTSVSTAY           LQISSLKADD           TAVYFCSRSR    100
                                            GKNEAWFAYW           GQGTLVTVSS           ASTKGPSVFP           LAPSSKSTSG           GTAALGCLVK    150
                                            DYFPEPVTVS           WNSGALTSGV           HTFPAVLQSS           GLYSLSSVVT           VPSSSLGTQT    200
                                            YICNVNHKPS           NTKVDKRVEP           KSCDKTHTCP           PCPAPELLGG           PSVFLFPPKP    250
                                            KDTLMISRTP           EVTCVVVDVS           HEDPEVKFNW           YVDGVEVHNA           KTKPREEQYN    300
                                            STYRVVSVLT           VLHQDWLNGK           EYKCKVSNKA           LPAPIEKTIS           KAKGQPREPQ    350
                                            VYTLPPSREE           MTKNQVSLTC           LVKGFYPSDI           AVEWESNGQP           ENNYKTTPPV    400
                                            LDSDGSFFLY           SKLTVDKSRW           QQGNVFSCSV           MHEALHNHYT           QKSLSLSPGK    450

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIQLTQSPLS           LPVTLGQPAS           ISCRSSQSLV           HRNGNTYLHW           FQQRPGQSPR    50'
                                            LLIYTVSNRF           SGVPDRFSGS           GSGTDFTLKI           SRVEAEDVGV           YFCSQSSHVP    100'
                                            PTFGAGTRLE           IKRTVAAPSV           FIFPPSDEQL           KSGTASVVCL           LNNFYPREAK    150'
                                            VQWKVDNALQ           SGNSQESVTE           QDSKDSTYSL           SSTLTLSKAD           YEKHKVYACE    200'
                                            VTHQGLSSPV           TKSFNRGEC                                                                    219'

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            22-96      22''-96''    23'-93'     23'''-93''' 139'-199' 139'''-199''' 147-203 147''-203''
                                            219'-223 219'''-223'' 229-229'' 232-232'' 264-324 264''-324'' 370-428 370''-428''



 mirabegronum
 mirabegron                                 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]=
                                            amino}ethyl)phenyl]acetamide

 mirabégron                                 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phényléthyl]=
                                            amino}éthyl)phényl]acétamide

 mirabegrón                                 2-(2-amino-1,3-tiazol-4-il)-N-[4-(2-{[(2R)-2-fenil-2-hidroxietil]amino}=
                                            etil)fenil]acetamida

                                            C21H24N4O2S

                                                      H OH
                                                                   H
                                                                   N                                               S
                                                                                                    O
                                                                                                                            NH2
                                                                                                N                   N
                                                                                                H


                                                                                                                                                237
Recommended INN: List 60                                     WHO Drug Information, Vol. 22, No.3, 2008




 monepantelum
 monepantel                N-{2-cyano-1-[(2S)-5-cyano-2-(trifluoromethyl)phenoxy]propan-2-yl}-
                           4-(trifluoromethylsulfanyl)benzamide

 monépantel                N-{(1S)-1-cyano-2-[5-cyano-2-(trifluorométhyl)-1-méthylphénoxy]-
                           4-[(trifluorométhyl)sulfanyl]benzamide

 monepantel                N-{2-ciano-1-[(2S)-5-ciano-2-(trifluorometil)fenoxi]propan-2-il}-
                           4-(trifluorometilsulfanil)benzamida

                           C20H13F6N3O2S

                                            O H3C          CN             CF3
                                                                 O
                                                   N
                                                   H
                           F3C
                                 S
                                                                          CN



 nelivaptanum
 nelivaptan                (2S,4R)-1-{(3R)-5-chloro-1-[(2,4-dimethoxybenzene)sulfonyl]-
                           3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl}-4-hydroxy-
                           N,N-dimethylpyrrolidine-2-carboxamide

 nélivaptan                (2S,4R)-1-{(3R)-5-chloro-1-[(2,4-diméthoxyphényl)sulfonyl]-
                           3-(2-méthoxyphényl)-2-oxo-2,3-dihydro-1H-indol-3-yl}-4-hydroxy-
                           N,N-diméthylpyrrolidine-2-carboxamide

 nelivaptán                (2S,4R)-1-{(3R)-5-cloro-1-[(2,4-dimetoxibenceno)sulfonil]-
                           3-(2-metoxifenil)-2-oxo-2,3-dihidro-1H-indol-3-il}-4-hidroxi-
                           N,N-dimetilpirrolidina-2-carboxamida

                           C30H32ClN3O8S

                           H3CO
                                               O       H3C
                                           S       O
                                                         N CH
                                                   O          3
                                      OCH3 N
                                                       O H

                                                       N
                                                                     OH
                                 Cl                    O        H
                                                           CH3




 nesbuvirum
 nesbuvir                  5-cyclopropyl-2-(4-fluorophenyl)-6-[N-(2-hydroxyethyl)=
                           methanesulfonamido]-N-methyl-1-benzofuran-3-carboxamide

 nesbuvir                  5-cyclopropyl-2-(4-fluorophényl)-6-[(2-hydroxyéthyl)(méthylsulfonyl)=
                           amino]-N-méthyl-1-benzofurane-3-carboxamide

 nesbuvir                  5-ciclopropil-2-(4-fluorofenil)-6-[N-(2-hidroxietil)metanosulfonamido]-
                           N-metil-1-benzofuran-3-carboxamida




238
WHO Drug Information, Vol. 22, No.3, 2008                                                 Recommended INN: List 60


                                            C22H23FN2O5S

                                                    O
                                                       CH3
                                                   O S
                                                       N            O
                                            HO
                                                                                      F


                                                                         NH
                                                                  O
                                                                         CH3



 odanacatibum
 odanacatib                                 (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-
                                            trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}=
                                            pentanamide

 odanacatib                                 (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-méthyl-2-({(1S)-2,2,2-
                                            trifluoro-1-[4'-(méthylsulfonyl)biphényl-4-yl]éthyl}amino)pentanamide

 odanacatib                                 (2S)-N-(1-cianociclopropil)-4-fluoro-4-metil-2-{[(1S)-2,2,2-trifluoro-
                                            1-{4'-(metanosulfonil)-[1,1'-bifenil]-4-il}etil]amino}pentanamida

                                            C25H27F4N3O3S

                                                                               CH3
                                                                           F
                                                                                    CH3
                                                                   F3C   H      H
                                                                                      H
                                                                                      N    CN
                                                                           N
                                                                           H
                                                                                 O

                                            H3C
                                                  S
                                                 O O



 omacetaxini mepesuccinas
 omacetaxine mepesuccinate                  1-[(1S,3aR,14bS)-2-methoxy-1,5,6,8,9,14b-hexahydro-
                                            4H-cyclopenta[a][1,3]dioxolo[4,5-h]pyrrolo[2,1-b][3]benzazepin-1-yl]
                                            4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate

 mépésuccinate d’omacétaxine                (2R)-2-hydroxy-2-(4-hydroxy-4-méthylpentyl)butanedioate de
                                            1-[(1S,3aR,14bS)-2-méthoxy-1,5,6,8,9,14b-hexahydro-
                                            4H-cyclopenta[a][1,3]dioxolo[4,5-h]pyrrolo[2,1-b][3]benzazépin-1-yle]
                                            et de 4-méthyle

 mepesuccinato de omacetaxina               (2R)-2-hidroxi-2-(4-hidroxi-4-metilpentil)butanodioato de
                                            1-[(1S,3aR,14bS)-2-metoxi-1,5,6,8,9,14b-hexahidro-
                                            4H-ciclopenta[a][1,3]dioxolo[4,5-h]pirrolo[2,1-b][3]benzazepin-1-ilo]
                                            y de 4-metilo




                                                                                                                     239
Recommended INN: List 60                                               WHO Drug Information, Vol. 22, No.3, 2008


                           C29H39NO9

                                                                   O CH3
                              HO CH3
                                               HO
                                                                   O
                           H3 C                                          OCH3
                                                               O
                                                      O H
                                                        H
                                               O
                                                                          N
                                               O


 otelixizumabum*
 otelixizumab              immunoglobulin G1, anti-(human CD3E) humanized/chimeric
                           monoclonal TRX4 (ChAglyCD3); humanized gamma1 heavy chain
                           299N>A [humanized VH (Homo sapiens FR/Rattus sp. CDR) (119
                           residues [8.8.12])- Homo sapiens IGHG1*01, 180N>A (CH2 84.4)]
                           (222-216’)-disulfide with chimeric lambda light chain 111G>R [Rattus
                           sp. V-LAMBDA (110 residues [8.3.9])-Homo sapiens IGLC2*01,
                           1G>R (1.5)] ; (228-228”: 231-231”)-bisdisulfide dimer

 otélixizumab              immunoglobuline G1, anti-(CD3E humain) anticorps monoclonal
                           humanisé/chimérique TRX4 (ChAglyCD3); chaîne lourde gamma1
                           humanisée 299N>A [VH humanisé (Homo sapiens FR/Rattus sp.
                           CDR) (119 residus [8.8.12])- Homo sapiens IGHG1*01, 180N>A
                           (CH2 84.4) (222-216’)-disulfure avec la chaîne lambda chimérique
                           111G>R [Rattus sp. V-LAMBDA (110 residues [8.3.9])-Homo
                           sapiens IGLC2*01, 1G>R (1.5)] ; dimère (228-228”: 231-231”)-
                           bidisulfure

 otelixizumab              inmunoglobulina G1, anti-(CD3E humano) anticuerpo monoclonal
                           humanizado/quimérico TRX4 (ChAglyCD3); cadena pesada
                           gamma1 humanizada 299N>A [VH humanizada (Homo sapiens
                           FR/Rattus sp. CDR) (119 residuos [8.8.12])- Homo sapiens
                           IGHG1*01, 180N>A (CH2 84.4) (222-216’)-disulfuro con la cadena
                           lambda quimérica 111G>R [Rattus sp. V-LAMBDA (110 residuos
                           [8.3.9])-Homo sapiens IGLC2*01, 1G>R (1.5)] ; dímero (228-
                           228”: 231-231”)-bisdisulfuro

                           C6448H9954N1718O2016S42

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLLESGGG LVQPGGSLRL SCAASGFTFS                               SFPMAWVRQA           PGKGLEWVST     50
                           ISTSGGRTYY RDSVKGRFTI SRDNSKNTLY                               LQMNSLRAED           TAVYYCAKFR    100
                           QYSGGFDYWG QGTLVTVSSA STKGPSVFPL                               APSSKSTSGG           TAALGCLVKD    150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                               LYSLSSVVTV           PSSSLGTQTY    200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                               CPAPELLGGP           SVFLFPPKPK    250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                               VDGVEVHNAK           TKPREEQYAS    300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                               PAPIEKTISK           AKGQPREPQV    350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                               VEWESNGQPE           NNYKTTPPVL    400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                               HEALHNHYTQ           KSLSLSPGK     449

                           Light chain / Chaîne légère / Cadena ligera
                           DIQLTQPNSV           STSLGSTVKL             SCTLSSGNIE         NNYVHWYQLY           EGRSPTTMIY     50'
                           DDDKRPDGVP           DRFSGSIDRS             SNSAFLTIHN         VAIEDEAIYF           CHSYVSSFNV    100'
                           FGGGTKLTVL           RQPKAAPSVT             LFPPSSEELQ         ANKATLVCLI           SDFYPGAVTV    150'
                           AWKADSSPVK           AGVETTTPSK             QSNNKYAASS         YLSLTPEQWK           SHRSYSCQVT    200'
                           HEGSTVEKTV           APTECS                                                                       216'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           22-96      22''-96''    22'-91'    22'''-91''' 138'-197' 138'''-197''' 146-202 146''-202''
                           215'-222 215'''-222'' 228-228'' 231-231'' 263-323 263''-323'' 369-427 369''-427''




240
WHO Drug Information, Vol. 22, No.3, 2008                                                           Recommended INN: List 60




 pegloticasum*
 pegloticase                                tetramer α4 of des-(1-5)-[6-threonine,45-threonine,290-lysine,
                                            300-serine]uricase (EC 1.7.3.3, urate oxidase) from Sus scrofa
                                            (porcine), non acetylated, of which some of the lysine 6-amine
                                            residues are engaged in a carbamate linkage with a monomethylic
                                            ether of polyoxyethylene (macrogol)

 pégloticase                                tétramère α4 du des-(1-5)-[6-thréonine,45-thréonine,290-lysine,
                                            300-sérine]uricase (EC 1.7.3.3, urate oxydase) de Sus scrofa (porc)
                                            non acétylé dont certaines fonctions 6-amine de lysines sont
                                            engagées dans une liaison carbamate avec un éther
                                            monométhylique de polyoxyéthylène (macrogol)

 pegloticasa                                tetrámero α4 de la des-(1-5)-[6-treonina,45-treonina,290-lisina,
                                            300-serina]uricasa (EC 1.7.3.3, urato oxidasa) de Sus scrofa (porc)
                                            no acetilada algunas de cuyas funciones 6-amino de las lisinas
                                            forman uniones carbamato con un éter monometílico de
                                            polioxietileno (macrogol)

                                            C6196H9720N1632O1792S32

                                                                                        O
                                                                          O                     R
                                                                   H3C              O       N
                                                                                            H
                                                                                   n



                                            H2N-R: Peptide monomer / Peptide monomère / Peptido monómero
                                                 TYKKN         DEVEFVRTGY     GKDMIKVLHI        QRDGKYHSIK     EVATTVQLTL      50
                                            SSKKDYLHGD         NSDVIPTDTI     KNTVNVLAKF        KGIKSIETFA     VTICEHFLSS     100
                                            FKHVIRAQVY         VEEVPWKRFE     KNGVKHVHAF        IYTPTGTHFC     EVEQIRNGPP     150
                                            VIHSGIKDLK         VLKTTQSGFE     GFIKDQFTTL        PEVKDRCFAT     QVYCKWRYHQ     200
                                            GRDVDFEATW         DTVRSIVLQK     FAGPYDKGEY        SPSVQKTLYD     IQVLTLGQVP     250
                                            EIEDMEISLP         NIHYLNIDMS     KMGLINKEEV        LLPLDNPYGK     ITGTVKRKLS     300
                                            SRL                                                                               303



 preladenantum
 preladenant                                2-(furan-2-yl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl]piperazin-
                                            1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

 préladénant                                2-(furan-2-yl)-7-(2-{4-[4-(2-méthoxyéthoxy)phényl]pipérazin-
                                            1-yl}éthyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

 preladenant                                2-(furan-2-il)-7-(2-{4-[4-(2-metoxietoxi)fenil]piperazin-1-il}etil)-
                                            7H-pirazolo[4,3-e][1,2,4]triazolo[1,5-c]pirimidin-5-amina

                                            C25H29N9O3

                                                O
                                                           N             N
                                                                         N
                                                                                    N
                                                       N       N
                                                                   N                        N
                                                           H2N
                                                                                                                    O
                                                                                                           O            CH3




                                                                                                                                241
Recommended INN: List 60                                           WHO Drug Information, Vol. 22, No.3, 2008


 radiprodilum
 radiprodil                    2-{4-[(4-fluorophenyl)methyl]piperidin-1-yl}-2-oxo-N-(2-oxo-
                               2,3-dihydro-1,3-benzoxazol-6-yl)acetamide

 radiprodil                    2-{4-[(4-fluorophényl)méthyl]pipéridin-1-yl}-2-oxo-N-(2-oxo-
                               2,3-dihydrobenzoxazol-6-yl)acétamide

 radiprodil                    2-{4-[(4-fluorofenil)metil]piperidin-1-il}-2-oxo-N-(2-oxo-2,3-dihidro-
                               1,3-benzoxazol-6-il)acetamida

                               C21H20FN3O4

                                     H
                                     N
                                                           O
                               O
                                                                    N
                                     O                N                                F
                                                      H
                                                               O



 remogliflozini etabonas
 remogliflozin etabonate       5-methyl-1-(propan-2-yl)-4-({4-[(propan-2-yl)oxy]phenyl}methyl)-
                               1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside

 étabonate de rémogliflozine   6-O-(éthoxycarbonyl)-β-D-glucopyranoside de 5-méthyl-4-{[4-(1-
                               méthyléthoxy)phényl]méthyl}-1-(1-méthyléthyl)-1H-pyrazol-3-yle

 etabonato de remogliflozina   6-O-(etoxicarbonil)-β-D-glucopiranósido de 5-metil-1-(propan-2-il)-
                               4-({4-[(propan-2-il)oxi]fenil}metil)-1H-pirazol-3-ilo

                               C26H38N2O9

                                                                     CH3

                                                               O        CH3




                                                                           CH3
                                                                                 CH3
                               H3C       O       O
                                                                            N
                                             O             O O          N        CH3
                                                      OH
                                                 HO
                                                           OH



 retosibanum
 retosiban                     (3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-
                               (2-methyl-1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl]piperazine-
                               2,5-dione

 rétosiban                     (3R,6R)-3-(2,3-dihydro-1H-indén-2-yl)-1-[(1R)-1-(2-méthyloxazol-
                               4-yl)-2-(morpholin-4-yl)-2-oxoéthyl]-6-[(1S)-1-méthylpropyl]=
                               pipérazine-2,5-dione

 retosibán                     (3R,6R)-6-[(2S)-butan-2-il]-3-(2,3-dihidro-1H-inden-2-il)-1-[(1R)-1-(2-
                               metil-1,3-oxazol-4-il)-2-(morfolin-4-il)-2-oxoetil]piperazina-2,5-diona




242
WHO Drug Information, Vol. 22, No.3, 2008                                                                      Recommended INN: List 60


                                            C27H34N4O5

                                                                                 CH3 CH3
                                                                     O H

                                                             HN                      H O
                                                                         N
                                                                                           N
                                                             H                         H
                                                                     O                               O
                                                                             N
                                                                                     O
                                                                     H3C




 riociguatum
 riociguat                                  methyl N-(4,6-diamino-2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo=
                                            [3,4-b]pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate

 riociguat                                  (4,6-diamino-2-{1-[(2-fluorophényl)méthyl]-1H-pyrazolo[3,4-b]pyridin-
                                            3-yl}pyrimidin-5-yl)méthylcarbamate de méthyle

 riociguat                                  (4,6-diamino-2-{1-[(2-fluorofenil)metil]-1H-pirazolo[3,4-b]piridin-
                                            3-il}pirimidin-5-il)metilcarbamato de metilo

                                            C20H19FN8O2

                                                                                 NH2       CH3
                                                                                           N         O
                                                                         N                               CH3
                                                             N                                 O
                                            F                                    N         NH2
                                                         N


                                                         N




 rolofyllinum
                                                                                               3,7
 rolofylline                                1,3-dipropyl-8-(tricyclo[3.3.1.0 ]nonan-3-yl)-3,7-dihydro-1H-purin-
                                            2,6-dione
                                                                                               3,7
 rolofylline                                1,3-dipropyl-8-(tricyclo[3.3.1.0 ]non-3-yl)-3,7-dihydro-1H-purine-
                                            2,6-dione
                                                                                           3,7
 rolofyllina                                1,3-dipropil-8-(triciclo[3.3.1.0 ]nonan-3-il)-3,7-dihidro-1H-purina-
                                            2,6-diona

                                            C20H28N4O2

                                                                 O
                                            H3C                              H
                                                                             N
                                                         N

                                                     O           N           N

                                                                         CH3




                                                                                                                                    243
Recommended INN: List 60                                              WHO Drug Information, Vol. 22, No.3, 2008


 tenatumomabum*
 tenatumomab               immunoglobulin G2b, anti-[human tenascin C (TNC, hexabrachion,
                           HBX) Mus musculus] monoclonal antibody ST2146; gamma2b heavy
                           chain (Mus musculus VH [8.8.13]-IGHG2B*02 from clone ST2146)
                           (135-219')-disulfide with kappa light chain (Mus musculus V-KAPPA
                           [11.3.9]-IGKC*01 from clone ST 2146); (229-229'':232-232'':235-
                           235'':238-238'')-tetradisulfide dimer

 ténatumomab               immunoglobuline G2b, anti-[tenascine C humaine (TNC,
                           hexabrachion, HBX) Mus musculus] anticorps monoclonal murin
                           ST2146; chaîne lourde gamma2b (Mus musculus VH [8.8.13]-
                           IGHG2B*02 du clone ST2146) (135-219')-disulfure avec la chaîne
                           légère kappa (Mus musculus V-KAPPA [11.3.9]-IGKC*01 du clone
                           ST 2146); dimère (229-229'':232-232'':235-235'':238-238'')-
                           tétradisulfide

 tenatumomab               inmunoglobulina G2b, anti-[tenascina C humana (TNC,
                           hexabrachion, HBX) Mus musculus] anticuerpo monoclonal murino
                           ST2146; cadena pesada gamma2b (Mus musculus VH [8.8.13]-
                           IGHG2B*02 del clon ST2146) (135-219')-disulfuro con la cadena
                           ligera kappa (Mus musculus V-KAPPA [11.3.9]-IGKC*01 del clon ST
                           2146); dímero (229-229'':232-232'':235-235'':238-238'')-tetradisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EIQLQQSGPE            LVKPGASVKV              SCKASGYAFT           SYNMYWVKQS             HGKSLEWIGY   50
                           IDPYNGVTSY            NQKFKGKATL              TVDKSSSTAY           MHLNSLTSED             SAVYYCARGG   100
                           GSIYYAMDYW            GQGTSVTVSS              AKTTPPSVYP           LAPGCGDTTG             SSVTLGCLVK   150
                           GYFPESVTVT            WNSGSLSSSV              HTFPALLQSG           LYTMSSSVTV             PSSTWPSQTV   200
                           TCSVAHPASS            TTVDKKLEPS              GPISTINPCP           PCKECHKCPA             PNLEGGPSVF   250
                           IFPPNIKDVL            MISLTPKVTC              VVVDVSEDDP           DVQISWFVNN             VEVHTAQTQT   300
                           HREDYNSTIR            VVSTLPIQHQ              DWMSGKEFKC           KVNNKDLPSP             IERTISKIKG   350
                           LVRAPQVYIL            PPPAEQLSRK              DVSLTCLVVG           FNPGDISVEW             TSNGHTEENY   400
                           KDTAPVLDSD            GSYFIYSKLN              MKTSKWEKTD           SFSCNVRHEG             LKNYYLKKTI   450
                           SRSPGK                                                                                                 456

                           Light chain/ Chaîne légère / Cadena ligera
                           DIVMTQAAPS            VPVTPGESVS              ISCRSSKSLL           HSNGNTYLYW             FLQRPGQSPQ   50
                           LLIYRMSNLA            SGVPDRFSGS              GSGTAFTLRI           SRVEAEDVGV             YYCMQHLEYP   100
                           LTFGAGTKLE            LKRADAAPTV              SIFPPSSEQL           TSGGASVVCF             LNNFYPKDIN   150
                           VKWKIDGSER            QNGVLNSWTD              QDSKDSTYSM           SSTLTLTKDE             YERHNSYTCE   200
                           ATHKTSTSPI            VKSFNRNEC                                                                        219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Bold and underlined Cysteins are those involved in disulphide bridges.




 tertomotidum
 tertomotide               human telomerase reverse transcriptase (EC 2.7.7.49)-(611-626)-
                           peptide (telomerase catalytic subunit fragment)

 tertomotide               télomérase transcriptase réverse humaine (EC 2.7.7.49)-(611-626)-
                           peptide (fragment de la sous-unité catalytique de la télomérase)

 tertomotida               transcriptasa inversa humana telomerasa (EC 2.7.7.49)-(611-626)-
                           péptido (fragmento de la subunidad catalítica de la telomerasa

                           C85H146N26O21

                           H Glu         Ala      Arg      Pro      Ala       Leu      Leu      Thr       Ser

                                Arg      Leu       Arg      Phe         Ile   Pro      Lys OH
                                 10                                                     16




244
WHO Drug Information, Vol. 22, No.3, 2008                                                                       Recommended INN: List 60


 tigatuzumabum*
 tigatuzumab                                immunoglobulin G1, anti-[Homo sapiens TNFRSF10B (tumor
                                            necrosis factor receptor superfamily member 10b, DR5, TRAIL-R2,
                                            CD262)] humanized monoclonal TRA-8 (or CS-1008); gamma1
                                            heavy chain [humanized VH (Homo sapiens FR/Mus musculus CDR)
                                            [8.8.12] -Homo sapiens IGHG1*03] (222-213')-disulfide with kappa
                                            light chain [humanized V-KAPPA (Homo sapiens FR/Mus musculus
                                            CDR) [6.3.8] -Homo sapiens IGKC*01]; (228-228'':231-231'')-
                                            bisdisulfide dimer

 tigatuzumab                                mmunoglobuline G1, anti-[Homo sapiens TNFRSF10B (membre 10b
                                            de la superfamille des récepteurs du facteur de nécrose tumorale,
                                            DR5, TRAIL-R2, CD262)] anticorps monoclonal humanisé TRA-8 (ou
                                            CS-1008); chaîne lourde gamma1 [VH humanisé (Homo sapiens
                                            FR/Mus musculus CDR) [8.8.12] - Homo sapiens IGHG1*03] (222-
                                            213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé
                                            (Homo sapiens FR/Mus musculus CDR) [6.3.8] -Homo sapiens
                                            IGKC*01]; dimère (228-228'':231-231'')-bisdisulfure

 tigatuzumab                                inmunoglobulina G1, anti-[Homo sapiens TNFRSF10B (miembro 10b
                                            de la superfamilia de receptores del factor de necrosis tumoral, DR5,
                                            TRAIL-R2, CD262)] anticuerpo monoclonal humanizado TRA-8
                                            (o CS-1008); cadena pesada gamma1 [VH humanizada (Homo
                                            sapiens FR/Mus musculus CDR) [8.8.12] - Homo sapiens
                                            IGHG1*03] (222-213')-disulfuro con la cadena ligera kappa
                                            [V-KAPPA humanizada (Homo sapiens FR/Mus musculus CDR)
                                            [6.3.8] -Homo sapiens IGKC*01]; dímero (228-228'':231-231'')-
                                            bisdisulfuro

                                            C6406H9924N1716O2012S46

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG           LVQPGGSLRL           SCAASGFTFS           SYVMSWVRQA           PGKGLEWVAT     50
                                            ISSGGSYTYY           PDSVKGRFTI           SRDNAKNTLY           LQMNSLRAED           TAVYYCARRG    100
                                            DSMITTDYWG           QGTLVTVSSA           STKGPSVFPL           APSSKSTSGG           TAALGCLVKD    150
                                            YFPEPVTVSW           NSGALTSGVH           TFPAVLQSSG           LYSLSSVVTV           PSSSLGTQTY    200
                                            ICNVNHKPSN           TKVDKRVEPK           SCDKTHTCPP           CPAPELLGGP           SVFLFPPKPK    250
                                            DTLMISRTPE           VTCVVVDVSH           EDPEVKFNWY           VDGVEVHNAK           TKPREEQYNS    300
                                            TYRVVSVLTV           LHQDWLNGKE           YKCKVSNKAL           PAPIEKTISK           AKGQPREPQV    350
                                            YTLPPSREEM           TKNQVSLTCL           VKGFYPSDIA           VEWESNGQPE           NNYKTTPPVL    400
                                            DSDGSFFLYS           KLTVDKSRWQ           QGNVFSCSVM           HEALHNHYTQ           KSLSLSPGK     449

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIQMTQSPSS           LSASVGDRVT ITCKASQDVG                     TAVAWYQQKP           GKAPKLLIYW    50'
                                            ASTRHTGVPS           RFSGSGSGTD FTLTISSLQP                     EDFATYYCQQ           YSSYRTFGQG    100'
                                            TKVEIKRTVA           APSVFIFPPS DEQLKSGTAS                     VVCLLNNFYP           REAKVQWKVD    150'
                                            NALQSGNSQE           SVTEQDSKDS TYSLSSTLTL                     SKADYEKHKV           YACEVTHQGL    200'
                                            SSPVTKSFNR           GEC        213'

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            22-96 22''-96'' 23'-88' 23'''-88''' 133'-193' 133'''-193''' 146-202 146''-202''
                                            213'-222 213'''-222'' 228-228'' 231-231'' 263-323 263''-323'' 369-427 369''-427''




 velaglucerasum alfa*
 velaglucerase alfa                         human glucosylceramidase (EC 3.2.1.45 or
                                            beta-glucocerebrosidase), glycoform α

 vélaglucérase alfa                         glucosylcéramidase humaine (EC 3.2.1.45 ou
                                            bêta-glucocérébrosidase), glycoform α

 velaglucerasa alfa                         glucosilceramidasa humana (EC 3.2.1.45 o
                                            beta-glucocerebrosidasa), glicoforma α




                                                                                                                                                245
Recommended INN: List 60                                            WHO Drug Information, Vol. 22, No.3, 2008


                           C2532H3850N672O711S16

                           ARPCIPKSFG           YSSVVCVCNA           TYCDSFDPPT            FPALGTFSRY           ESTRSGRRME    50
                           LSMGPIQANH           TGTGLLLTLQ           PEQKFQKVKG            FGGAMTDAAA           LNILALSPPA   100
                           QNLLLKSYFS           EEGIGYNIIR           VPMASCDFSI            RTYTYADTPD           DFQLHNFSLP   150
                           EEDTKLKIPL           IHRALQLAQR           PVSLLASPWT            SPTWLKTNGA           VNGKGSLKGQ   200
                           PGDIYHQTWA           RYFVKFLDAY           AEHKLQFWAV            TAENEPSAGL           LSGYPFQCLG   250
                           FTPEHQRDFI           ARDLGPTLAN           STHHNVRLLM            LDDQRLLLPH           WAKVVLTDPE   300
                           AAKYVHGIAV           HWYLDFLAPA           KATLGETHRL            FPNTMLFASE           ACVGSKFWEQ   350
                           SVRLGSWDRG           MQYSHSIITN           LLYHVVGWTD            WNLALNPEGG           PNWVRNFVDS   400
                           PIIVDITKDT           FYKQPMFYHL           GHFSKFIPEG            SQRVGLVASQ           KNDLDAVALM   450
                           HPDGSAVVVV           LNRSSKDVPL           TIKDPAVGFL            ETISPGYSIH           TYLWRRQ      497

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           4-16 18-23

                           Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                           Asn-19 Asn-59 Asn-146 Asn-270 Asn-462



 veltuzumabum*
 veltuzumab                immunoglobulin G1, anti-[Homo sapiens CD20 (MS4A1, membrane-
                           spanning 4-domains subfamily A member 1, B lymphocyte surface
                           antigen B1, Leu-16, Bp35)] humanized monoclonal IMMU-106 (or
                           hA20); gamma1 heavy chain [humanized VH (Homo sapiens
                           FR/Mus musculus CDR) [8.8.14] -Homo sapiens IGHG1*03]
                           (224-213')-disulfide with kappa light chain [humanized V-KAPPA
                           (Homo sapiens FR/Mus musculus CDR) [5.3.9] -Homo sapiens
                           IGKC*01]; (230-230'':233-233'')-bisdisulfide dimer

 veltuzumab                immunoglobuline G1, anti-[Homo sapiens CD20 (MS4A1, membre 1
                           de la sous-famille A à 4 domaines transmembranaires, antigène de
                           surface B1 des lymphocytes B, Leu-16, Bp35)] anticorps monoclonal
                           humanisé IMMU-106 (ou hA20); chaîne lourde gamma1 [VH
                           humanisé (Homo sapiens FR/Mus musculus CDR) [8.8.14] - Homo
                           sapiens IGHG1*03] (224-213')-disulfure avec la chaîne légère kappa
                           [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR) [5.3.9]
                           -Homo sapiens IGKC*01]; dimère (230-230'':233-233'')-bisdisulfure

 veltuzumab                inmunoglobulina G1, anti-[Homo sapiens CD20 (MS4A1, miembro 1
                           de la subfamilia A con 4 dominios transmembranarios , antígeno de
                           superficie B1 de los linfocitos B, Leu-16, Bp35)] anticuerpo
                           monoclonal humanizado IMMU-106 (ou hA20); cadena pesada
                           gamma1 [VH humanizado (Homo sapiens FR/Mus musculus CDR)
                           [8.8.14] - Homo sapiens IGHG1*03] (224-213')-disulfuro con la
                           cadena ligera kappa [V-KAPPA humanizado (Homo sapiens FR/Mus
                           musculus CDR) [5.3.9] -Homo sapiens IGKC*01]; dímero
                           (230-230'':233-233'')-bisdisulfuro

                           C6458H9918N1706O2026S46

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQQSGAE           VKKPGSSVKV           SCKASGYTFT           SYNMHWVKQA           PGQGLEWIGA    50
                           IYPGMGDTSY           NQKFKGKATL           TADESTNTAY           MELSSLRSED           TAFYYCARST    100
                           YYGGDWYFDV           WGQGTTVTVS           SASTKGPSVF           PLAPSSKSTS           GGTAALGCLV    150
                           KDYFPEPVTV           SWNSGALTSG           VHTFPAVLQS           SGLYSLSSVV           TVPSSSLGTQ    200
                           TYICNVNHKP           SNTKVDKRVE           PKSCDKTHTC           PPCPAPELLG           GPSVFLFPPK    250
                           PKDTLMISRT           PEVTCVVVDV           SHEDPEVKFN           WYVDGVEVHN           AKTKPREEQY    300
                           NSTYRVVSVL           TVLHQDWLNG           KEYKCKVSNK           ALPAPIEKTI           SKAKGQPREP    350
                           QVYTLPPSRE           EMTKNQVSLT           CLVKGFYPSD           IAVEWESNGQ           PENNYKTTPP    400
                           VLDSDGSFFL           YSKLTVDKSR           WQQGNVFSCS           VMHEALHNHY           TQKSLSLSPG    450
                           K                                                                                                 451

                           Light chain / Chaîne légère / Cadena ligera
                           DIQLTQSPSS           LSASVGDRVT           MTCRASSSVS           YIHWFQQKPG           KAPKPWIYAT    50'
                           SNLASGVPVR           FSGSGSGTDY           TFTISSLQPE           DIATYYCQQW           TSNPPTFGGG    100'
                           TKLEIKRTVA           APSVFIFPPS           DEQLKSGTAS           VVCLLNNFYP           REAKVQWKVD    150'
                           NALQSGNSQE           SVTEQDSKDS           TYSLSSTLTL           SKADYEKHKV           YACEVTHQGL    200'
                           SSPVTKSFNR           GEC                                                                          213'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           22-96      22''-96''    23'-87'     23'''-87''' 133'-193' 133'''-193''' 148-204 148''-204''
                           213'-224 213'''-224'' 230-230'' 233-233'' 265-325 265''-325'' 371-429 371''-429''




246
WHO Drug Information, Vol. 22, No.3, 2008                                                   Recommended INN: List 60


 viquidacinum
 viquidacin                                 (3R,4R)-4-{(3S)-3-[3-fluoro-6-methoxyquinolin-4-yl]-
                                            3-hydroxypropyl}-1-{2-[(thiophen-2-yl)sulfanyl]ethyl}piperidine-
                                            3-carboxylic acid

 viquidacine                                acide (3R,4R)-4-[(3S)-3-(3-fluoro-6-méthoxyquinoléin-4-yl)-
                                            3-hydroxypropyl]-1-[2-(thiophén-2-ylsulfanyl)éthyl]pipéridine-
                                            3-carboxylique

 viquidacina                                ácido (3R,4R)-4-{(3S)-3-[3-fluoro-6-metoxiquinolin-4-il]-
                                            3-hidroxipropil}-1-{2-[(tiofen-2-il)sulfanil]etil}piperidina-3-carboxílico

                                            C25H29FN2O4S2

                                                                                        OCH3

                                                                H   CO2H     H OH

                                                 S
                                                                        H
                                                              N                         N
                                                     S                         F




                                                                                                                         247
 Recommended INN: List 60                                                 WHO Drug Information, Vol. 22, No.3, 2008




                               AMENDMENTS TO PREVIOUS LISTS
                       MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                           MODIFICACIONES A LAS LISTAS ANTERIORES


 Recommended International Nonproprietary Names (Rec. INN): List 59
 Dénominations communes internationales recommandées (DCI Rec.): Liste 59
 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
 (WHO Drug Information, Vol. 22, No. 1, 2008)

 p. 43   suprimáse                      insertése
         albinterferón alfa2b           albinterferón alfa-2b

 p. 48   supprimer                      insérer
         céftaroline fosamil            ceftaroline fosamil




 * Electronic structure available on Mednet: http://mednet.who.int/
 * Structure électronique disponible sur Mednet: http://mednet.who.int/
 * Estructura electrónica disponible en Mednet: http://mednet.who.int/




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




 248
